BCG Shortage: Salvaging Bladder Cancer Care When Standard Care Is Scarce w/ Dr. Luckenbaugh | Ep. 20 скачать в хорошем качестве

BCG Shortage: Salvaging Bladder Cancer Care When Standard Care Is Scarce w/ Dr. Luckenbaugh | Ep. 20

How do you effectively treat your bladder cancer population with an insufficient supply of BCG? Dr. Amy Luckenbaugh, a urologic oncologist at Vanderbilt University Medical Center, joins host Dr. Ruchika Talwar to highlight challenges and solutions to managing bladder cancer amidst ongoing BCG shortages. --- This podcast is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025. --- SYNPOSIS Dr. Luckenbaugh and Dr. Talwar delve into the history and significance of BCG in bladder cancer treatment, exploring the reasons behind the shortages and discussing various coping strategies, including split dosing and alternative intravesical therapies like gemcitabine, docetaxel, and the new mitomycin hydrogel. The conversation also covers emerging treatments for high-risk patients, the role of radical cystectomy, and the importance of standardization and innovation in dealing with medication shortages. Dr. Luckenbaugh highlights the importance of patient quality of life, cost considerations, and the need for resilient pharmaceutical supply chains. --- TIMESTAMPS 00:00 - Introduction 01:56 - History and Importance of BCG in Bladder Cancer 03:21 - Challenges and Shortages of BCG 06:36 - Managing BCG Shortages in Clinical Practice 12:33 - New Alternatives and Treatments for Bladder Cancer 23:28 - The Role of Cystectomy in Bladder Cancer Treatment 26:12 - Future Directions and Final Thoughts --- RESOURCES BCG Shortage AUA Recommendations: https://www.auanet.org/about-us/bcg-s... Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre: https://pmc.ncbi.nlm.nih.gov/articles... Bladder Cancer Advocacy Network (BCAN): https://bcan.org/ Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION) https://pubmed.ncbi.nlm.nih.gov/39446... FDA Approves Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer: https://www.fda.gov/drugs/resources-i... TAR-200 - SunRISe-3 Study: https://www.jnjmedicalconnect.com/pro... First results from TAR-200 - SunRISe-1 Study: https://www.jnj.com/media-center/pres... N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review: https://pmc.ncbi.nlm.nih.gov/articles... #ONC20 #bladdercancer #urology #oncology